WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206423

CAS#: 1228013-30-6

Description: CC-223 is an orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor CC-223 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers.

Price and Availability


USD 150
USD 1950

USD 450
USD 3250

USD 750
USD 7950

CC-223, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 200mg may be 2 weeks.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 206423
Name: CC-223
CAS#: 1228013-30-6
Chemical Formula: C21H27N5O3
Exact Mass: 397.21139
Molecular Weight: 397.48
Elemental Analysis: C, 63.46; H, 6.85; N, 17.62; O, 12.08

Synonym: CC-223; CC 223; CC223.

IUPAC/Chemical Name: 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one


InChi Code: InChI=1S/C21H27N5O3/c1-21(2,28)17-9-4-13(10-22-17)16-11-23-19-20(25-16)26(18(27)12-24-19)14-5-7-15(29-3)8-6-14/h4,9-11,14-15,28H,5-8,12H2,1-3H3,(H,23,24)/t14-,15-

SMILES Code: OC(C)(C)C(N=C1)=CC=C1C(N=C2N3[C@@H]4CC[C@H](CC4)OC)=CN=C2NCC3=O

Technical Data

Red to pink solid powder

>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T,
Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS,
Chopra R, Hege K, Munster PN. A phase I dose-escalation study to assess safety,
tolerability, pharmacokinetics, and preliminary efficacy of the dual
mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or
multiple myeloma. Cancer. 2015 Oct 1;121(19):3481-90. doi: 10.1002/cncr.29422.
Epub 2015 Jul 15. PubMed PMID: 26177599.

2: Mortensen DS, Perrin-Ninkovic SM, Shevlin G, Zhao J, Packard G, Bahmanyar S,
Correa M, Elsner J, Harris R, Lee BG, Papa P, Parnes JS, Riggs JR, Sapienza J,
Tehrani L, Whitefield B, Apuy J, Bisonette RR, Gamez JC, Hickman M, Khambatta G,
Leisten J, Peng SX, Richardson SJ, Cathers BE, Canan SS, Moghaddam MF, Raymon HK,
Worland P, Narla RK, Fultz KE, Sankar S. Discovery of mammalian target of
rapamycin (mTOR) kinase inhibitor CC-223. J Med Chem. 2015 Jul 9;58(13):5323-33.
doi: 10.1021/acs.jmedchem.5b00626. Epub 2015 Jun 26. PubMed PMID: 26083478.

3: Mortensen DS, Fultz KE, Xu S, Xu W, Packard G, Khambatta G, Gamez JC, Leisten
J, Zhao J, Apuy J, Ghoreishi K, Hickman M, Narla RK, Bissonette R, Richardson S,
Peng SX, Perrin-Ninkovic S, Tran T, Shi T, Yang WQ, Tong Z, Cathers BE, Moghaddam
MF, Canan SS, Worland P, Sankar S, Raymon HK. CC-223, a Potent and Selective
Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther.
2015 Jun;14(6):1295-305. doi: 10.1158/1535-7163.MCT-14-1052. Epub 2015 Apr 8.
PubMed PMID: 25855786.

4: Ashworth RE, Wu J. Mammalian target of rapamycin inhibition in hepatocellular
carcinoma. World J Hepatol. 2014 Nov 27;6(11):776-82. doi:
10.4254/wjh.v6.i11.776. Review. PubMed PMID: 25429315; PubMed Central PMCID:

(last updated: 4/19/2016)